Curevac Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Curevac Contact Number

Contact CureVac

5 hours ago Curevac.com Show details

49 69 7680

CureVac AG Germany, Frankfurt Site. Get directions. Clinical Development. Schumannstr. 27. 60325 Frankfurt. T +49 69 7680 587 – 0. F +49 69 7680 587 – 2222.

Category: Contact SupportShow more

CureVac Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

Company Type For Profit. Contact Email [email protected]curevac.com. Phone Number +49707198830. CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own

Founded: 2000
Founder: Florian von der Mulbe

Category: Contact NumberShow more

CureVac to Shift Focus of COVID19 Vaccine Development to

4 hours ago Finance.yahoo.com Show details

1 day ago · CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations CureVac, Tübingen, …

Category: Contact NumberShow more

CureVac manu switchup as it shelves COVID vax

Just Now Bioprocessintl.com Show details

CureVac manufacturing switch-up as it shelves COVID-19 vax. by Millie Nelson Wednesday, October 13, 2021 8:04 am. CureVac will shift its manufacturing setup to produce clinical material for second-generation mRNA vaccine candidates as it abandons CVnCoV. Just one month ago, CureVac dropped two contract development manufacturing organization’s

Category: Contact NumberShow more

Inside CureVac's odyssey to produce a COVID19 vaccine

3 hours ago Marketplace.org Show details

The road to developing a COVID-19 vaccine has been a long one for CureVac, as its rivals continue to ship billions of doses to countries around the …

Category: Contact NumberShow more

CureVac Funding, Financials, Valuation & Investors

6 hours ago Crunchbase.com Show details

CureVac has raised a total of $1.8B in funding over 13 rounds. Their latest funding was raised on Feb 2, 2021 from a Post-IPO Equity round. CureVac is registered under the ticker NASDAQ:CVAC . Their stock opened with $16.00 in its Aug 14, 2020 IPO. CureVac is …

Category: Contact NumberShow more

CureVac Drops COVID19 Vaccine, Pins Hope on Next

Just Now Usnews.com Show details

CureVac said it would abandon its application for approval from the European Medicines Agency for its first COVID-19 vaccine candidate, CVnCoV, after late-stage trials delivered disappointing

Category: Contact NumberShow more

CureVac drops Covid vaccine to focus on new jab with GSK

3 hours ago Ft.com Show details

Curevac’s US-listed shares fell 8 per cent. The jab developed with GSK has shown better results in early-phase animal trials, and appears to elicit 10 times more antibodies than the first vaccine.

Category: Contact NumberShow more

Covid Updates: U.S. Will Open Borders With Canada and

4 hours ago Nytimes.com Show details

The German company CureVac announced on to commit to two coronavirus tests if they are not and to participate in a new contact tracing system.

Category: Contact NumberShow more

CureVac Abandons Covid Shot After Disappointing Trial

9 hours ago Bnnbloomberg.ca Show details

1 day ago · CureVac’s first-generation Covid vaccine delivered disappointing trial results earlier this year. The shot was 48% effective at preventing disease of any severity -- well behind the more than 90% rates shown by messenger RNA shots from Pfizer Inc.-BioNTech SE and Moderna Inc. Like those shots, CureVac’s also relies on mRNA, a technology

Category: Contact NumberShow more

Curevac abandons Covid shot after disappointing trial

7 hours ago Business-standard.com Show details

1 day ago · CureVac’s first-generation Covid vaccine delivered disappointing trial results earlier this year. The shot was 48% effective at preventing disease of any severity -- well behind the more than 90% rates shown by messenger RNA shots from Pfizer Inc.-BioNTech SE and Moderna Inc.

Category: Contact NumberShow more

CureVac LinkedIn

9 hours ago Nl.linkedin.com Show details

CureVac 36.483 volgers op LinkedIn. We fight for human health - we are the RNA people We fight for human health – we are the RNA people CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes.

Category: Contact NumberShow more

CureVac drops COVID19 vaccine, pins hope on next

8 hours ago News.trust.org Show details

1 day ago · CureVac drops COVID-19 vaccine, pins hope on next-generation shots. * CureVac says 450 mln eur from EU is non-refundable. * Trials showed 47% efficacy for original vaccine. * …

Category: Contact NumberShow more

CureVac GmbH Company Profile and News Bloomberg Markets

3 hours ago Bloomberg.com Show details

Company profile page for CureVac GmbH including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

CureVac N.V. (CVAC) Company Profile & Facts Yahoo Finance

5 hours ago Finance.yahoo.com Show details

See the company profile for CureVac N.V. (CVAC) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Category: Contact NumberShow more

CureVac and Bayer CVnCoV

5 hours ago Genengnews.com Show details

CureVac also disclosed that it successfully completed recruiting in the pivotal Phase IIb/III HERALD study (NCT04652102; EudraCT Number: 2020 …

Category: Contact NumberShow more

CureVac Announces Closing of Initial Public Offering

6 hours ago Accesswire.com Show details

49 7071 9883

CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA. CureVac Investor Relation Contact Dr. Sarah Fakih, Vice President Investor Relations CureVac, Tübingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949 [email protected] CureVac Media Contact Thorsten Schüller, Director Corporate Communications

Category: Contact NumberShow more

CureVac COVID19 vaccine Wikipedia

1 hours ago En.wikipedia.org Show details

CureVac COVID-19 vaccine. The CureVac COVID-19 vaccine is a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). As of April 2021 it is currently in Phase III clinical trials. The manufacturer …

Category: Contact NumberShow more

CureVac's COVID19 vaccine attracts rising interest

8 hours ago News.yahoo.com Show details

German biotech firm CureVac said it has seen the number of requests for its experimental COVID-19 vaccine increase over the past few days, as concerns over rare side effects have hit some other coronavirus shots. Remarks made to Reuters by a CureVac spokesman on the growing interest on Thursday were underscored by Chief Executive Franz-Werner Haas in an analyst call on …

Category: Contact NumberShow more

CureVac N.V. (NASDAQ: CVAC) Stock: Bulls Must See This

8 hours ago Stocksregister.com Show details

The number of analysts that have assigned CVAC a recommendation rating is 4. Out of them, 3 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged CureVac N.V. (CVAC) as Underweight, while 0 advise Sell.

Category: Contact NumberShow more

Is CureVac BV (CVAC) Stock a Good Value Wednesday?

1 hours ago Investorsobserver.com Show details

CureVac BV (CVAC) stock is trading at $42.74 as of 1:51 PM on Wednesday, Oct 13, a gain of $1.56, or 3.79% from the previous closing price of $41.18. The stock has traded between $41.40 and $44.11 so far today. Volume today is light.

Category: Contact NumberShow more

Working at CureVac Glassdoor

6 hours ago Glassdoor.com Show details

Glassdoor gives you an inside look at what it's like to work at CureVac, including salaries, reviews, office photos, and more. This is the CureVac company profile. All content is posted anonymously by employees working at CureVac.

Category: Contact NumberShow more

CureVac Announces Financial Results for the Second Quarter

4 hours ago Accesswire.com Show details

49 7071 9883

CureVac Investor Relations Contact Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations CureVac, Tübingen, Germany T: +49 7071 9883-1298 M: +49 160 90 496949 [email protected] CureVac Media Contact Anna Kamilli, Manager Communications CureVac, Tübingen, Germany T: +49 7071 9883-1684 [email protected]

Category: Contact NumberShow more

CureVac Wikipedia

6 hours ago En.wikipedia.org Show details

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee.CureVac had approximately 240 employees in …

Category: Contact NumberShow more

Boehringer Ingelheim and CureVac announce collaboration to

4 hours ago Boehringer-ingelheim.us Show details

Ingelheim and Tübingen, Germany, and Ridgefield, Conn., September 18, 2014 – Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine in …

Category: Contact NumberShow more

CureVac, Sanofi Pasteur, and InCellArt Collaborate on €

2 hours ago Genengnews.com Show details

The option agreement signed between Sanofi and CureVac in parallel with the DARPA collaboration covers pre-agreed license terms for the development …

Category: Cell PhoneShow more

Contact us The Pharma Letter

7 hours ago Thepharmaletter.com Show details

Contact us. The Pharma Letter. 39 to 43 Putney High Street. Putney. London. SW15 1SP. For trial and subscription enquiries please email [email protected] For editorial enquiries, press releases and events please email [email protected] For all other queries please email [email protected]

Category: Contact SupportShow more

CureVac FierceBiotech

4 hours ago Fiercebiotech.com Show details

The scoop: CureVac, alongside BioNTech and Moderna, is one of the biotechs that put mRNA on the map.It suffered the field’s first big clinical …

Category: Tech SupportShow more

Curevac gets $300 million grant to hurry up COVID19 vaccine

7 hours ago News.yahoo.com Show details

German biotech firm Curevac said on Friday it had won nearly $300 million in government funding to speed up work on its prototype COVID-19 vaccine and build capacity to produce it at scale. The Tuebingen-based startup, valued at $10 billion after floating last month on Nasdaq, is one of a number of firms designing vaccines based on molecules carrying a genetic code called messenger …

Category: Contact NumberShow more

Is CureVac BV (CVAC) Stock a Good Value Wednesday?

9 hours ago Investorsobserver.com Show details

CureVac BV (CVAC) stock is higher by 2.12% while the S&P 500 is down -0.26% as of 1:03 PM on Wednesday, Sep 8. CVAC is higher by $1.45 from the previous closing price of $68.50 on volume of 158,426 shares. Over the past year the S&P 500 has gained 35.31% while CVAC is …

Category: Contact NumberShow more

CureVac is an opportunity for a Covid19 vaccine public

5 hours ago Qz.com Show details

But CureVac still did the work to set up the kind of supply chain needed to pump out 1 billion doses by the end of 2020: Raw materials reserved, factories …

Category: Contact NumberShow more

CureVac's COVID19 vaccine attracts rising interest CTV News

3 hours ago Ctvnews.ca Show details

German biotech firm CureVac said it has seen the number of requests for its experimental COVID-19 vaccine increase over the past few …

Category: Contact NumberShow more

2 Reasons This COVID Vaccine Latecomer Could Gain Major

2 hours ago Fool.com Show details

Category: Contact NumberShow more

CureVac N.V. (CVAC) Stock Price, News, Quote & History

Just Now Ca.finance.yahoo.com Show details

36 billion as of June 30, 2021TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 16, 2021 / CureVac N. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the second quarter and first half of 2021 and

Category: Contact NumberShow more

CureVac’s mRNA Covid Vaccine Looks Just in Time After J&J

Just Now Bnnbloomberg.ca Show details

CureVac’s mRNA Covid Vaccine Looks Just in Time After J&J Snag. (Bloomberg) -- CureVac NV is some five months behind the front-runner messenger RNA vaccines against Covid-19. But after the industry’s recent setbacks, that’s starting to look like good timing. The German company will unveil clinical trial results soon and has said it should

Category: Contact NumberShow more

Why Is Everyone Talking About CureVac Stock? The Motley Fool

6 hours ago Fool.com Show details

As for the 47% efficacy figure, we don't know if it increased or decreased with the number of cases. For the sake of argument, if CVnCoV only had, say, 30% overall efficacy in the first interim

Category: Contact NumberShow more

Preclinical data shows higher antibody action from CureVac

7 hours ago Homelandprepnews.com Show details

Contact; Search Articles. “The mRNA technology is a key strategic priority for us, and we are investing significantly in a number of mRNA programs focused on the collaboration with CureVac,” Dr. Rino Rappuoli, Chief Scientist and head of GSK Vaccines R&D, said. GSK and CureVac have been working together on such technology since July

Category: Contact NumberShow more

CureVac vaccine disappoints in key study amid

6 hours ago Biopharmadive.com Show details

Their vaccines entered Phase 3 testing within days of one another last summer, which, given the high number of COVID-19 cases in the U.S. at the time, resulted in fast clinical trial progress. CureVac received support from the U.S. and German governments last year as well.

Category: Contact NumberShow more

CureVac fails in pivotal COVID19 vaccine trial with 47%

4 hours ago Yahoo.com Show details

(Reuters) -German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main …

Category: Contact NumberShow more

Coronavirus: Commission approves contract with CureVac to

1 hours ago Europeansting.com Show details

Today, the European Commission approved a fifth contract with the European pharmaceutical company CureVac, which provides for the initial purchase of 225 million doses on behalf of all EU Member States, plus an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.

Category: Contact NumberShow more

Sven Koch – Associate Director ImmunoMonitoring – CureVac

5 hours ago De.linkedin.com Show details

The primary endpoint of the study is the number of patients experiencing Grade >3 treatment-related adverse events. Pharmacodynamic analyses include the assessment of immune responses to the antigens encoded by CV9202 and others not included in the panel (antigen spreading) and standard efficacy assessments.

Title: Associate Director Immuno …
Location: Bayern, Deutschland

Category: Contact NumberShow more

CureVac gets OK to start testing mRNA COVID19 vaccine in

9 hours ago Fiercebiotech.com Show details

CureVac has received regulatory clearance to start a phase 1 trial of its COVID-19 vaccine. The start of the 168-subject study comes days after …

Category: Contact NumberShow more

CureVac reveals early data for mRNAbased COVID19 vaccine

Just Now Pmlive.com Show details

mRNA technology has been in the spotlight during the race to develop a COVID-19 vaccine, with a number of companies utilising this research area to develop innovative vaccines for the novel coronavirus. That includes CureVac, Pfizer and BioNTech, and …

Category: Contact NumberShow more

What Kind Of Shareholders Hold The Majority In CureVac N.V

8 hours ago Ca.finance.yahoo.com Show details

Shareholders would probably be interested to learn that insiders own shares in CureVac N.V.. The insiders have a meaningful stake worth US$450m. It is good to see this level of investment. You can check here to see if those insiders have been buying recently. General Public Ownership. The general public holds a 21% stake in CureVac.

Category: Contact NumberShow more

CureVac stock soars after $213.3M IPO Drug Delivery Business

4 hours ago Drugdeliverybusiness.com Show details

Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday.. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million.Currently, shares of CVAC are trading up 30.2% at $72.77.

Category: Contact NumberShow more

Coronavirus vaccine developer CureVac raises $213 million

8 hours ago Nasdaq.com Show details

CureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, a person familiar with the matter said, setting the stage for …

Category: Contact NumberShow more

Doris Mesia Vela Medical Director Infectious Diseases

2 hours ago Be.linkedin.com Show details

Senior Manager Clinical & Medical Affairs-Emerging Markets. GSK. Jun 2011 - Feb 20131 year 9 months. Wavre. - In charge of malaria and flu vaccines in Emerging Markets. - Supporting HPV and Hepatitis vaccines activities. - Collaborating with the operations team on feasibility studies, CDPs.

Title: Medical Director Infectious Diseases
Location: Brussels Metropolitan
Connections: 329

Category: Contact NumberShow more

CUREVAC AKTIE Schätzungen Prognosen & Erwartungen A2P71U

5 hours ago Finanzen.net Show details

CUREVAC Schätzungen: Hier finden Sie einen Überblick über die erwartete Entwicklung der wichtigsten Kennzahlen von CUREVAC wie z.B. Umsatz, Gewinn, KGV, Dividende und Buchwert. Die …

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

How is curevac setting itself up for success?

So, CureVac is setting itself up for success when it comes to delivering vaccines to customers. The company also has another logistic strength. And it has to do with the vaccine candidate itself. Like Moderna and Pfizer, CureVac has developed an mRNA vaccine.

When does curevac covid 19 vaccine come out?

The CureVac COVID-19 vaccine is a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). As of April 2021 it is currently in Phase III clinical trials. The manufacturer markets the vaccine under the name CVnCoV.

Who are the competitors of curevac nv?

CureVac (NASDAQ: CVAC) is working on mRNA coronavirus vaccine candidates. If it's successful, mRNA vaccine giants Moderna and Pfizer will face competition.

When did curevac announce final late stage clinical data?

On June 30, CureVac (NASDAQ: CVAC) announced final late-stage clinical data for its mRNA coronavirus vaccine candidate CVnCoV. Nobody was more disappointed than the German government, which had invested more than 300 million euros into the vaccine candidate's research and development efforts.

Brand New Updated

Popular Brands

Costco
Cisco
Cae
Ccu
Crh